Editas Medicine Management
Management criteria checks 1/4
Editas Medicine's CEO is Gilmore O’Neill, appointed in Jun 2022, has a tenure of 3.42 years. total yearly compensation is $5.13M, comprised of 13% salary and 87% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth $469.96K. The average tenure of the management team and the board of directors is 1.6 years and 6.8 years respectively.
Key information
Gilmore O’Neill
Chief executive officer
US$5.1m
Total compensation
| CEO salary percentage | 13.01% |
| CEO tenure | 3.4yrs |
| CEO ownership | 0.2% |
| Management average tenure | 1.6yrs |
| Board average tenure | 6.8yrs |
Recent management updates
Recent updates
Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm?
Oct 14Editas Medicine, Inc. (NASDAQ:EDIT) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
Sep 09
There's Reason For Concern Over Editas Medicine, Inc.'s (NASDAQ:EDIT) Massive 42% Price Jump
Jul 22Editas Medicine (NASDAQ:EDIT) Will Have To Spend Its Cash Wisely
Jun 17Editas Medicine, Inc.'s (NASDAQ:EDIT) Price Is Right But Growth Is Lacking After Shares Rocket 28%
May 21Editas Medicine, Inc. (NASDAQ:EDIT) Looks Inexpensive After Falling 35% But Perhaps Not Attractive Enough
Mar 30We're A Little Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Rate
Mar 13Editas And Intellia: Strategic Shifts And Long-Term Investment Potential
Jan 17Little Excitement Around Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues As Shares Take 34% Pounding
Nov 20Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week
Nov 06Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?
Sep 26Editas Medicine: A Risk/Reward Worth Considering
Sep 25Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet
Aug 23Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 10Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results
May 12The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%
Apr 23Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Mar 09Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch
Feb 28New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)
Dec 15Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher
May 10Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?
Jan 19Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline
Oct 18Editas Medicine started at neutral at BofA due to competition in gene editing programs
Sep 29We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely
Sep 13Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies
Aug 23CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -US$237m |
| Mar 31 2025 | n/a | n/a | -US$251m |
| Dec 31 2024 | US$5m | US$667k | -US$237m |
| Sep 30 2024 | n/a | n/a | -US$211m |
| Jun 30 2024 | n/a | n/a | -US$193m |
| Mar 31 2024 | n/a | n/a | -US$166m |
| Dec 31 2023 | US$2m | US$641k | -US$153m |
| Sep 30 2023 | n/a | n/a | -US$195m |
| Jun 30 2023 | n/a | n/a | -US$206m |
| Mar 31 2023 | n/a | n/a | -US$219m |
| Dec 31 2022 | US$9m | US$356k | -US$220m |
Compensation vs Market: Gilmore's total compensation ($USD5.13M) is above average for companies of similar size in the US market ($USD1.49M).
Compensation vs Earnings: Gilmore's compensation has increased whilst the company is unprofitable.
CEO
Gilmore O’Neill (61 yo)
Dr. Gilmore O’Neill, M.B., M. M.SC., serves as Member of Scientific Advisory Board of AavantiBio, Inc. since February 2022. He is President & CEO of Editas Medicine, Inc. from June 01, 2022 and serves as i...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.4yrs | US$5.13m | 0.17% $ 470.0k | |
| Co-Founder & Scientific Advisory Board Member | 12.8yrs | no data | no data | |
| Co-Founder & Scientific Advisory Board Member | 12.8yrs | no data | no data | |
| Senior VP & CFO | less than a year | no data | 0.018% $ 50.4k | |
| Executive VP and Chief Technical & Quality Officer | 1.6yrs | no data | no data | |
| Executive VP & Chief Scientific Officer | 2.3yrs | US$1.73m | 0.035% $ 96.7k | |
| Senior VP of Corporate Communications & Investor Relations | no data | no data | no data | |
| Senior VP | less than a year | no data | no data | |
| Senior VP & Chief Business Officer | less than a year | no data | no data | |
| Senior Vice President of Development and Program Leadership | less than a year | no data | no data |
Experienced Management: EDIT's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | no data | US$5.13m | 0.17% $ 470.0k | |
| Co-Founder & Scientific Advisory Board Member | no data | no data | no data | |
| Co-Founder & Scientific Advisory Board Member | no data | no data | no data | |
| Independent Director | 8.5yrs | US$210.56k | 0.0022% $ 6.1k | |
| Independent Chairman | 7.8yrs | US$151.30k | 0.075% $ 208.5k | |
| Independent Director | 2.6yrs | US$140.05k | 0% $ 0 | |
| Independent Director | 6.8yrs | US$144.78k | 0% $ 0 | |
| Independent Director | 4.1yrs | US$147.83k | 0% $ 0 |
Experienced Board: EDIT's board of directors are considered experienced (6.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/02 08:13 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Editas Medicine, Inc. is covered by 26 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Joel Beatty | Baird |
| Huidong Wang | Barclays |